Sensus Healthcare, Inc. (NASDAQ:SRTS) Stock Has Consensus Target Price of $5.83

Sensus Healthcare, Inc. (NASDAQ:SRTS) has earned an average rating of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $5.83.

A number of equities research analysts have recently issued reports on the stock. Alliance Global Partners reissued a “buy” rating on shares of Sensus Healthcare in a research note on Monday, August 17th. Lake Street Capital lowered their price objective on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating for the company in a research report on Friday, August 14th. Finally, Weiss Ratings downgraded shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th.

Insider Buying and Selling

In other news, Director Eric Sachetta purchased 37,537 shares of the stock in a transaction dated Friday, August 28th. The stock was acquired at an average cost of $3.44 per share, for a total transaction of $129,127.28. Following the completion of the transaction, the director directly owned 267,480 shares in the company, valued at approximately $920,131.20. This represents a 16.32% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Insiders acquired 120,171 shares of company stock worth $405,230 in the last 90 days. 10.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Sensus Healthcare

Several institutional investors and hedge funds have recently modified their holdings of SRTS. EP Wealth Advisors LLC acquired a new position in Sensus Healthcare in the 2nd quarter valued at about $49,000. BlackRock Inc. purchased a new stake in Sensus Healthcare during the second quarter worth about $252,000. Bank of New York Mellon Corp acquired a new stake in shares of Sensus Healthcare during the second quarter worth about $303,000. Finally, North Star Investment Management Corp. acquired a new stake in shares of Sensus Healthcare during the first quarter worth about $500,000. Hedge funds and other institutional investors own 25.30% of the company’s stock.

Sensus Healthcare Stock Performance

Shares of SRTS opened at $2.76 on Tuesday. The company’s 50-day moving average price is $3.09 and its 200 day moving average price is $3.25. Sensus Healthcare has a 12-month low of $2.66 and a 12-month high of $5.49.

Sensus Healthcare (NASDAQ:SRTS) last announced its earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%. The company had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $4.60 million.

About Sensus Healthcare

Sensus Healthcare, Inc (NASDAQ: SRTS) develops and markets non-invasive medical devices for dermatology and oncology. The company’s primary focus is superficial radiation therapy, a low-energy X-ray treatment designed to treat conditions affecting or located near the surface of the skin.

Its product portfolio includes the SRT-100 system and related platforms, which are used primarily in the treatment of non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as keloid scars.